Medspa Treatment Pricing Benchmarks (National & Regional)

Per-unit pricing for neuromodulators typically ranges $10–$15 nationally, with coastal metros and high-income markets trending toward $13–$15 and secondary markets toward $10–$12. A standard forehead/glabella/crow's feet treatment uses 20–25 units, yielding a patient charge of $200–$375. Allergan Aesthetics' Botox commands the highest per-unit reimbursement due to brand loyalty and longest track record; Dysport (Galderma) often prices 1–2 dollars lower per unit to gain share; Xeomin (Merz) and Jeuveau (Evolus) typically price at parity or slight discount to Dysport. Practices using loyalty programs (Alle for Allergan, Aspire for Galderma, Evolus Rewards) often offer tiered pricing or point-based discounts, which can compress effective per-unit realization by 5–10% but drive volume and retention. High-volume practices in competitive markets may price at the lower end; boutique or medically-led practices (dermatologists, plastic surgeons) often command 15–20% premiums. Subscription models (e.g., "Botox club" at $150–$200/month for standing treatments) are gaining traction in urban markets and can stabilize revenue but require patient commitment.

Per-syringe pricing for hyaluronic-acid fillers ranges $500–$900 nationally, with premium brands and deep-plane techniques at the higher end. Juvederm Ultra Plus and Restylane Lyft (for cheek volume) typically command $700–$900 per syringe in major metros; Restylane Refyne and Juvederm Volbella (for lips and fine lines) often price $600–$800. Secondary markets and high-volume practices may price $500–$650. Radiesse (calcium hydroxyapatite), a biostimulator, typically prices $600–$800 per syringe; Sculptra (poly-L-lactic acid), which requires multiple sessions, is often bundled at $1,200–$1,800 for a 3-vial series. Geographic variance is significant: New York, Los Angeles, Miami, and San Francisco practices often price 20–30% above national average; Midwest and rural markets 15–25% below. Practices offering "filler packages" (e.g., 2 syringes for $1,200) or loyalty discounts via Alle or Aspire may reduce per-syringe realization by 10–15%. Physician-led practices and those with strong brand positioning often sustain premium pricing; nurse-injector-only practices in saturated markets may compete on price, sometimes undercutting by 15–25%.

Energy-device pricing varies widely by modality and treatment area. IPL photofacial treatments (full face) typically range $300–$600 per session; packages of 4–6 sessions often discount to $250–$450 per session. Laser Genesis (non-ablative fractional laser for texture and rosacea) runs $400–$700 per session. RF microneedling (e.g., Morpheus8, Secret RF) commands premium pricing: $800–$1,500 per full-face treatment, with packages of 3 sessions at $2,000–$3,500 total. Radiofrequency skin tightening (monopolar RF, e.g., Thermage, or newer platforms like Cynosure Lutronic's XERF) ranges $1,500–$3,500 per treatment depending on area (face, neck, body) and device generation; newer, faster systems may command 10–15% premiums. Geographic and credential premiums are pronounced: dermatologist-led practices in major metros often price 20–30% above nurse-led practices in secondary markets. Device ownership vs. leasing affects pricing strategy; owned devices allow lower per-treatment cost and higher margin, supporting competitive pricing; leased devices require higher per-treatment revenue to break even. Practices often bundle energy treatments into packages (e.g., 3 RF microneedling + 6 IPL for $4,500–$6,000) to improve patient lifetime value and device utilization.

Many practices now price combination treatments—e.g., neuromodulator + filler in a single session—as a package rather than itemizing. A typical "full-face refresh" (20 units Botox + 1–2 syringes filler) might be priced $900–$1,400 as a package, vs. $200–$375 + $600–$900 itemized. This bundling strategy improves perceived value, increases average transaction size, and reduces administrative friction. Consultation fees ($50–$150) are common in dermatology-led or high-end practices; many medspa-only practices waive them to reduce friction. Touch-up visits (2–3 weeks post-injection) are often complimentary or discounted 20–30% to encourage patient retention and ensure satisfaction. Membership or subscription models (e.g., $200–$300/month for standing neuromodulator + filler) are growing in urban markets; they trade per-transaction margin for predictable revenue and patient lock-in. Loyalty programs via manufacturer platforms (Alle, Aspire, Evolus Rewards) typically offer 10–20% discounts on subsequent purchases, compressing effective per-unit/per-syringe realization but driving volume and repeat visits. Practices with strong social-media presence or celebrity/influencer clientele often command 20–40% premiums; practices in highly competitive markets or those targeting price-sensitive demographics may discount 15–25% below regional average.

Tier-1 metros (NYC, LA, Miami, San Francisco, Boston): Neuromodulator $13–$15/unit; filler $750–$900/syringe; RF microneedling $1,200–$1,500. Tier-2 metros (Chicago, Dallas, Atlanta, Seattle, Denver): Neuromodulator $11–$13/unit; filler $650–$800/syringe; RF microneedling $900–$1,200. Secondary markets and suburbs: Neuromodulator $10–$12/unit; filler $550–$700/syringe; RF microneedling $700–$1,000. Rural/underserved markets: Neuromodulator $9–$11/unit; filler $450–$600/syringe; RF microneedling $600–$900. Credential mix also drives regional variance: markets with high dermatologist/plastic-surgeon density (e.g., Miami, Beverly Hills) support higher pricing; markets dominated by nurse-injector-only practices or MSO roll-ups often see compressed pricing. Payer mix matters: practices serving high-net-worth or concierge patients can price 20–30% above average; practices in insurance-heavy markets (e.g., corporate wellness programs) may offer discounts. Seasonality affects pricing power: Q4 (holiday/New Year's resolutions) and spring (pre-summer) typically see higher demand and less price sensitivity; summer and January often see discounting and promotional pricing.

Understanding your cost of goods sold (COGS) is essential to pricing strategy. Neuromodulator COGS (wholesale cost per unit via Alle, Aspire, or direct) typically ranges $3–$6 per unit depending on volume tier and rebate program; at $12/unit retail, gross margin is 50–75%. Filler COGS (per syringe) ranges $150–$300 depending on brand, volume, and rebate tier; at $700/syringe retail, gross margin is 55–80%. Energy-device treatments have higher fixed costs (device acquisition, maintenance, staff training) but lower per-treatment COGS; gross margin on device treatments often ranges 60–75% after amortizing device cost. Practices using MSO or group-purchasing models (e.g., Allergan Aesthetics' direct-to-practice programs, or PE-backed roll-ups) may negotiate 10–20% better COGS than independent practices, allowing either lower pricing for market share or higher margin at parity pricing. Rebate programs (Alle, Aspire, Evolus Rewards) can add 5–15% to effective margin if you meet volume thresholds; practices should model rebate tiers into pricing strategy. Practices should regularly audit COGS vs. retail pricing to ensure margin targets (typically 60–70% gross margin on injectables, 65–75% on energy devices) are being met; if not, pricing should be adjusted or COGS renegotiated.